Galleri by Grail
GBG
Description
"Galleri by GRAIL" test detects shared cancer signals across more than 50 types using a simple blood sample. It identifies abnormal DNA linked to cancer and pinpoints the likely tissue of origin. Doctors use it for early detection, especially in high-risk individuals or those without symptoms. A positive result guides further testing or imaging. The Galleri test supports earlier intervention and offers a proactive way to assess broad cancer risk and inform personalized care decisions.
Test Category
Tumor Markers
Procedure
Non-Invasive
Sample Type
Blood – Serum
Units
Not Applicable
Procedure Category
Blood Draw
Test Group
Chronic Illness Group
Test Group Description
Chronic Illness Group: This group encompasses a range of tests specifically tailored to assess markers associated with chronic health conditions, providing comprehensive insights into the management and monitoring of chronic illnesses.
Optimal Range
For All Individuals:
Result: Negative: No abnormalities detected.
Normal Range
For All Individuals:
Result: Negative: No abnormalities detected.
Results That Differ From The Norm (Direct and Indirect Causes)
Abnormal results may indicate:
Cancer
Genetic factors (Inherited predisposition to certain cancers)
Key Reasons For Testing
Early Cancer Detection: Galleri by GRAIL detects multiple cancers early by identifying circulating tumor DNA (ctDNA), aiding timely intervention.
Cancer Risk Assessment: Evaluates cancer risk using ctDNA and biomarkers, supporting prevention and personalized screening.
Monitoring High-Risk Individuals: Tracks cancer risk in genetically predisposed or high-risk populations for early detection.
Comprehensive Screening: Detects various cancers, including those with limited screening options, improving outcomes.
Health Status Conditions It May Be Used To Assess
Currently, this test is not directly associated with any conditions listed on the Health Status page. However, it may be included as part of a broader set of tests linked to specific health conditions.
Some Prominent Medical Labs That May Offer This Test
Please note that this particular test has not been associated with any of the listed prominent medical labs. We recommend enquiring with your private physician or nearest hospital to determine where this specific test can be performed.
References
Important Note
Any medical procedure yielding results outside the norm may be directly or indirectly linked to the conditions outlined on this page. Various factors, including genetics, medication and supplement usage, recent illnesses, pregnancy, pre-test eating, smoking, and stress, can impact the test's outcome. Additionally, factors like false positives, false negatives, inaccurate analyses, and others can influence results.
Reference ranges, which help healthcare professionals interpret medical tests, may vary depending on age, gender, and other factors. They may also differ between laboratories due to variations in instruments and methods used. Optimal ranges are designed for preventive purposes, aiming to identify trends and potential risks early, while normal ranges reflect conventional laboratory values indicating no current disease or pathology. Your healthcare practitioner may have specific reasons for testing that deviate from the usual or may interpret results differently based on individual circumstances. Proper interpretation typically involves considering clinical findings and other diagnostic tests. Hence, it is crucial to provide your healthcare professionals with a comprehensive medical history, consult with them for result interpretation, and follow their guidance for potential re-testing or additional diagnostics.
Disclaimer
This content is provided solely for informative and educational purposes. It is not intended as a substitute for medical advice or treatment from a personal physician. Regarding the interpretation of their medical test results and/or specific health questions, it is recommended that all readers and viewers consult their physicians or other qualified health professionals. The publisher is not responsible for any adverse health effects that may result from reading or following the information in this educational content. Before beginning any nutrition, supplement, or lifestyle program, all viewers, especially those taking prescription or over-the-counter medications, should consult their physician or health care practitioner.
Please note that while prominent lab names are included in this content, we cannot guarantee that these labs offer all the tests mentioned. For confirmation, individuals should contact the labs directly or consult their medical practitioners. The information provided reflects general knowledge at the time of publication and may not include recent updates or emerging research. Readers should verify details with qualified professionals to ensure the most up-to-date and accurate guidance.
[1] Lennon AM, Buchanan AH, Kinde I, et al. Feasibility of blood testing combined with PET-CT to screen for cancers in healthy individuals: a prospective study. Science. 2020;369(6499).
[2] Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167-1177.
[3] Oxnard GR, Klein EA, Seiden MV, Hubbell E, Venn O, Jamshidi A. Blood-based early cancer detection: progress and challenges. Nat Rev Clin Oncol. 2022;19(5):273-286.
[4] Liu MC, Oxnard GR, Klein EA, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA from plasma. Ann Oncol. 2020;31(6):745-759.
[5] Lennon AM, Peter S, Kinde I, et al. Identification of early cancer signals using blood-based multi-analyte assays. Sci Transl Med. 2021;13(558).
[6] Cohen JD, Li L, Wang Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359(6378):926-930.
[7] Yu M, Liang X, Wang Y, et al. Blood-based early detection of cancer by next-generation sequencing. Nat Biomed Eng.2022;6(7):761-776.
[8] Ray S, Bonakdar M, Belford A, et al. Potential of DNA methylation markers in cell-free DNA for early multi-cancer detection. Cancer Cell Int. 2020;20(1):296.
[9] Haber DA, Velculescu VE. Blood-based analysis of cancer: circulating tumor cells and circulating tumor DNA. Science. 2014;339(6117):580-586.
[10] Bronkhorst AJ, Ungerer V, Holdenrieder S. The emerging role of cell-free DNA as a molecular marker for cancer management. Biomol Detect Quantif. 2019;17:100087.
[11] Parkinson CA, Gale D, Piskorz AM, et al. Exploratory analysis of TP53 mutations in circulating tumor DNA as biomarkers for response to treatment and survival in ovarian cancer patients. Clin Cancer Res. 2016;22(22):5320-5331.
[12] Li BT, Janku F, Jung B, et al. Circulating tumor DNA as a liquid biopsy for cancer. J Clin Oncol. 2019;37(10):1525-1545.
[13] Shin HT, Neal JW, Sunwoo JB, et al. Use of cell-free DNA from whole blood in clinical decision making for cancer diagnosis. Clin Cancer Res. 2020;26(18):4786-4794.
[14] Sun X, Dai J, Wang W, et al. Evaluation of liquid biopsy in detection of early-stage lung cancer. J Clin Invest.2021;131(8).
[15] Schrag D, McDonnell CH, Naduld L, et al. PATHFINDER: A Prospective Study of a Multi-Cancer Early Detection Blood Test. Presented at European Society of Medical Oncology (ESMO) Congress; September 9-13, 2022; Paris, France.